| Literature DB >> 35453242 |
Vanja Ljoljić Bilić1, Uroš M Gašić2, Dušanka Milojković-Opsenica3, Hrvoje Rimac1, Jadranka Vuković Rodriguez4, Josipa Vlainić5, Diana Brlek-Gorski6, Ivan Kosalec1.
Abstract
Followed by a buildup of its phytochemical profile, Erodium cicutarium is being subjected to antimicrobial investigation guided with its ethnobotanical use. The results of performed in vitro screening on Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans strains, show that E. cicutarium has antimicrobial activity, with a particular emphasis on clinical S. aureus strains-both the methicillin sensitive (MSSA) and the methicillin resistant (MRSA) S. aureus. Experimental design consisted of general methods (the serial microdilution broth assay and the agar well diffusion assay), as well as observing bactericidal/bacteriostatic activity through time (the "time-kill" assay), investigating the effect on cell wall integrity and biofilm formation, and modulation of bacterial hemolysis. Observed antibacterial activity from above-described methods led to further activity-guided fractionation of water and methanol extracts using bioautography coupled with UHPLC-LTQ OrbiTrap MS4. It was determined that active fractions are predominantly formed by gallic acid derivatives and flavonol glycosides. Among the most active phytochemicals, galloyl-shikimic acid was identified as the most abundant compound. These results point to a direct connection between galloyl-shikimic acid and the observed E. cicutarium antibacterial activity, and open several new research approaches for future investigation.Entities:
Keywords: Erodium cicutarium; MRSA; anti-hemolytic; bioautography; biofilm; fractionation; galloyl-shikimic acid; phenolic composition
Year: 2022 PMID: 35453242 PMCID: PMC9027144 DOI: 10.3390/antibiotics11040492
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Susceptibility of S. aureus clinical isolates used in the study determined with VITEK® 2 automated susceptibility testing system.
| Strain | Antibiotic/MIC a (μg/mL) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cefoxitin-Screen Test | Oxacillin | Gentamicin | Tobramycin | Levofloxacin | Moxyfloxacin | Erythromycin | Clindamycin | Linezolid | Teicoplanin | Vancomycin | Tetracycline | Tigecycline | Fosfomycin | Fusidic Acid | Trimethoprim/ | |
| - | 2 | ≤0.5 | ≤1 | 1 | 0.5 | ≤0.25 | ≤0.25 | 2 | 2 | 2 | ≤1 | ≤0.12 | 16 | ≤0.5 | ≤10 | |
| + | ≥4 | 1 | 4 | 4 | 2 | ≥8 | 1 | ≥8 | 8 | 8 | 2 | 0.25 | ≥8 | 1 | 160 | |
a MIC—minimal inhibitory concentration; b Collection of Microorganisms of the Department of Microbiology, Faculty of Pharmacy and Biochemistry University of Zagreb; c MSSA—methicillin sensitive S. aureus; d MRSA—methicillin resistant S. aureus.
In vitro antimicrobial activity screening of E. cicutarium water and methanolic extracts from four locations in Croatia (Podvinje, Plitvice, Trešnjevka, Buzin), for the agar well diffusion assay and the microdilution broth assay.
| Sample | MRSA f MFBF 10679 | MSSA g MFBF 10663 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± S.D. | |||||||||||
| ZI a (mm) | MIC b (mg/mL) | ZI a (mm) | MIC b (mg/mL) | ZI a (mm) | MIC b (mg/mL) | ZI a (mm) | MIC b (mg/mL) | ZI a (mm) | MIC b (mg/mL) | ||
| N = 5 | N = 3 | N = 5 | N = 3 | N = 5 | N = 3 | N = 5 | N = 3 | N = 5 | N = 3 | ||
| Podvinje | W d | 21 ± 1 1,2 | 8.33 ± 2.9 2,3 | 16 ± 1 2 | 5.00 ± 0.0 1,2,3 | 22 ± 2 3 | 3.33 ± 1.4 1 | 16 ± 1 1,2 | >20 | 6 ± 0 | >20 |
| M e | 19 ± 2 | 3.75 ± 2.2 | 19 ± 2 2,3 | 2.50 ± 0.0 | 22 ± 1 2,3 | 3.33 ± 1.4 | 15 ± 2 | 20.00 ± 0.0 3 | 15 ± 2 1 | >20 | |
| Plitvice | W d | 16 ± 2 2 | 10.00 ± 0.0 2,3 | 14 ± 2 *,2 | 10.00 ± 0.0 *,3 | 20 ± 2 3 | 10.00 ± 0.0 * | 13 ± 2 | >20 | 6 ± 0 | >20 |
| M e | 18 ± 1 | 10.00 ± 0.0 | 19 ± 1 3 | 4.17 ± 1.4 | 22 ± 1 2,3 | 3.33 ± 1.4 | 15 ± 1 3 | 20.00 ± 0.0 3 | 13 ± 1 2,3 | >20 | |
| Trešnjevka | W d | 12 ± 2 *,3 | 20.00 ± 0.0 * | 6 ± 0 *,3 | 10.00 ± 0.0 *,3 | 16 ± 1 3 | 6.67 ± 2.9 | 12 ± 1 *,3 | >20 | 6 ± 0 | >20 |
| M e | 17 ± 1 | 3.75 ± 2.2 | 16 ± 2 | 2.5 ± 0.0 | 20 ± 1 | 3.33 ± 1.4 | 15 ± 2 | 20.00 ± 0.0 3 | 11 ± 1 | >20 | |
| Buzin | W d | 20 ± 2 | 20.00 ± 0.0 * | 16 ± 2 | 20.00 ± 0.0 * | 20 ± 3 * | 6.67 ± 2.9 | 15 ± 1 | >20 | 6 ± 0 | >20 |
| M e | 19 ± 2 | 6.67 ± 2.9 | 13 ± 2 | 6.67 ± 2.9 | 19 ± 1 | 3.33 ± 1.4 | 12 ± 2 | 10.00 ± 0.0 | 6 ± 0 | >20 | |
| Gentamicin sulphate | 17±1 | 0.001 ± 0.0 | 13 ± 2 | 0.001 ± 0.000 | 12 ± 1 | 0.001 ± 0.000 | 12 ± 1 | 0.003 ± 0.000 | NT c | NT c | |
| Nystatin | NT c | 25 ± 1 | 0.03 ± 0.00 | ||||||||
a ZI, zone of growth inhibition for c = 20 mg/mL; b MIC, minimal inhibitory concentration; c NT, not tested; d W, water extract; e M, methanolic extract; f MRSA, methicillin resistant S. aureus; g MSSA, methicillin sensitive S. aureus; * statistically significant difference compared to the methanolic extract from the same location (p < 0.05, t-test); 1 statistically significant difference compared to same type of extract from locality Plitvice (p < 0.05, one-way ANOVA and Tukey’s post hoc test); 2 statistically significant difference compared to the same extract type from the Trešnjevka locality (p < 0.05, one-way ANOVA and Tukey’s post hoc test); 3 statistically significant difference compared to same extract type from the Buzin locality (p < 0.05, one-way ANOVA and Tukey’s post hoc test); Remark: statistical analysis was conducted separately for each assay.
Figure 1“Time-kill” assay of E. cicutarium water (Podvinje-W) and methanolic (Podvinje-M) extracts from the Podvinje locality on MSSA and MRSA strains (CFU, colony forming unit).
Figure 2Bacterial viability reduction (%) in the “time-kill” assay for E. cicutarium water (Podvinje-W) and methanolic (Podvinje-M) extracts from the Podvinje locality on MSSA and MRSA strains at predefined time points t0, t1, t3, t6, t9 i t24 (one-way ANOVA and Tukey’s post hoc test; *, p ≤ 0.05; **, p ≤ 0.01; ****, p ≤ 0.0001).
Figure 3S. aureus ATCC 6538 protein leakage after cell integrity loss when treated with E. cicutarium methanolic extract from the Podvinje locality (Podvinje-M) and Triton-X100, compared to a negative control (N = 3; mean ± S.D; one-way ANOVA and Tukey’s post hoc test; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.000).
Anti-biofilm activity of water (Podvinje-W) and methanolic (Podvinje-M) E. cicutarium extracts from the Podvinje locality on MSSA and MRSA (results shown as mean ± S.D; N = 3).
| Sample or Control | MSSA ATCC 6538 | MRSA MFBF 10679 | ||
|---|---|---|---|---|
| MBFIC50 a | MBFIC90 a | MBFIC50 a | MBFIC90 a | |
| µg/mL | ||||
| Podvinje-W | 1.05 ± 0.97 | 5095.37 ± 1143.88 | 61.84 ± 56.00 | 8509.34 ± 1268.83 |
| Podvinje-M | 0.41 ± 0.27 | 3083.98 ± 549.69 | 3.17 ± 5.30 | 8091.00 ± 477.24 |
| Gentamicin sulphate | 0.01 ± 0.01 | 0.99 ± 0.03 | 0.05 ± 0.03 | 1.66 ± 0.49 |
a MBFIC = minimal biofilm-forming inhibition concentration, at which bacterial biofilm mass was inhibited by 50% (MBFIC50) and 90% (MBFIC90), compared to negative control.
Figure 4Anti-hemolytic activity of E. cicutarium water (Podvinje-W) and methanolic (Podvinje-M) extracts from the Podvinje locality on MSSA and MRSA strains (*, statistically significant difference among c1 and c2; c1 = MIC/2; c2 = MIC/4; p ≤ 0.01; t-test).
Anti-hemolytic activity of E. cicutarium water (Podvinje-W) and methanolic (Podvinje-M) extracts from the Podvinje locality on MSSA and MRSA strains, expressed as relative hemolysis (%) and bovine hemoglobin equivalents (A540 = 0.0773c + 0.0393; A540—absorbance at 540 nm; c—bovine hemoglobin concentration in mg/mL; R² = 0.9995).
| Sample or Control | Hemoglobin Equivalents (mg/mL) | Relative Hemolysis (%) | ||
|---|---|---|---|---|
| MSSA ATCC 6538 | MRSA MFBF 10679 | MSSA ATCC 6538 | MRSA MFBF 10679 | |
| Podvinje-M | 5.36 | 5.33 | 70.50 ± 14.71 | 70.14 ± 14.22 |
| Podvinje-M | 6.56 | 7.41 | 84.15 ± 4.74 | 87.61 ± 7.57 |
| Podvinje-W | 3.47 | 3.90 | 49.30 ± 5.51 | 51.28 ± 4.00 |
| Podvinje-W | 4.55 | 6.60 | 62.90 ± 5.23 | 80.43 ± 6.66 |
| NC (M) | 7.53 | 7.97 | 100.00 ± 0.00 | 100.00 ± 0.00 |
| PC (V) | 7.73 | 8.42 | 100.00 ± 0.00 | 100.00 ± 0.00 |
| PC/Triton X-100 (2%) | 8.39 | 103.50 | ||
NC—negative control; PC—positive control.
Figure 5(A) Bioautography in situ—chromatograms of water (W) and methanolic (M) E. cicutarium extracts from the Podvinje locality (applied in triplicate) covered with inoculated MHA with S. aureus ATCC 6538 (1.5 × 106 CFU/mL) and stained with bacterial viability indicator TTC (1%, m/V). Zones of bacterial growth inhibition are yellow, while the parts with viable bacteria are in red. (B) Chromatograms of water (W) and methanolic (M) E. cicutarium extracts of from the Podvinje locality (applied in triplicate) on TLC silica gel F254 plates, developed with mobile phase acetonitrile/water/formic acid = 30:8:2 (v/v/v), and visualized with NSR (1%, m/V) at 366 nm. (C) Same chromatograms at 254 nm.
Phenolic composition of antimicrobially active fractions of E. cicutarium water (Podvinje-W) and methanolic (Podvinje-M) extracts from the Podvinje locality, isolated semi-preparatively based on bioautography with MSSA ATCC 6538, and analyzed via UHPLC-LTQ OrbiTrap MS4 in negative ionization mode.
| No | Compound Name | Molecular Formula, [M–H]- | Calculated Mass, [M–H]- | Exact Mass, [M–H]- | Δ mDa | MS2 Fragments, (% Base Peak) | MS3 Fragments, (% Base Peak) | MS4 Fragments, (% Base Peak) | Podvinje-M | Podvinje-W | |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| mg/kg GAE * | ||||||||||
|
| Galloyl hexoside isomer 1 | 2.84 |
| 331.06707 | 331.06312 | 3.95 | 125(12), 169(100), 170(8), 193(12), 211(28), 271(65), 272(9) | 125(100) | 81(33), 97(15), 107(100), 133(5) | 35.43 | 15.41 |
|
| Gallic acid | 3.88 |
| 169.01425 | 169.01234 | 1.91 | 124(4), 125(100) | 53(6), 79(17), 81(100), 83(3), 97(69), 107(16) | NA | 140.51 | 54.64 |
|
| Galloyl pentoside isomer 1 | 5.54 |
| 301.05651 | 301.05327 | 3.24 | 125(5), 149(55), 169(100), 170(7), 255(6), 256(5), 257(4) | 125(100) | 81(55), 97(20), 107(100) | 3.87 | 9.69 |
|
| Galloyl hexoside isomer 2 | 5.57 |
| 331.06707 | 331.06263 | 4.44 | 125(5), 169(100), 170(6), 223(3), 234(4), 285(3) | 125(100) | 81(61), 83(6), 97(100), 107(27), 239(16) | 9.02 | ND |
|
| Galloyl-shikimic acid | 5.85 |
| 325.05651 | 325.05217 | 4.34 | 125(9), 169(100), 170(4) | 125(100) | 53(5), 79(3), 81(47), 97(53), 107(100) | 375.42 | 531.45 |
|
| Galloyl pentoside isomer 2 | 5.95 |
| 301.05651 | 301.05302 | 3.49 | 125(4), 149(58), 169(100), 170(4) | 125(100) | 81(32), 84(3), 97(34), 107(100), 109(3) | 60.54 | 137.42 |
|
| Protocatechuic acid | 6.19 |
| 153.01933 | 153.01803 | 1.30 | 108(3), 109(100), 110(5) | 65(100), 81(62) | NA | 22.60 | 3.82 |
|
| Methylgalloyl hexoside isomer 1 | 6.44 |
| 345.08272 | 345.07854 | 4.18 | 183(100), 184(4) | 124(85), 168(100), 183(3) | 124(100) | 101.03 | 76.57 |
|
| Digalloyl hexoside | 6.50 |
| 483.07803 | 483.07317 | 4.86 | 169(12), 193(10), 211(14), 271(100), 272(11), 313(25), 331(22) | 169(12), 211(100) | 124(24), 165(10), 167(28), 168(100), 183(9) | 11.46 | 7.53 |
|
| Methylgalloyl hexoside isomer 2 | 6.81 |
| 345.08272 | 345.08100 | 1.72 | 183(100), 184(8), 299(12), 300(3), 323(3) | 124(100), 168(93) | 78(100), 96(25), 106(59) | 15.05 | ND |
|
| Corilagin | 7.13 |
| 633.07334 | 633.06856 | 4.78 | 275(17), 301(100), 302(13), 419(5), 463(20), 613(10), 614(7) | 185(34), 201(13), 229(61), 257(100), 284(24), 301(15) | 185(100), 201(15), 213(6), 229(83), 230(6) | 94.00 | 61.15 |
|
| Methylgallate | 7.29 |
| 183.02990 | 183.02832 | 1.58 | 124(100), 137(12), 153(12), 167(14), 168(100), 169(7), 183(9) | 124(100) | 78(100), 79(4), 106(45), 140(27) | 24.67 | 4.10 |
|
| Digalloyl-shikimic acid | 7.31 |
| 477.06746 | 477.06271 | 4.75 | 169(25), 263(76), 289(100), 290(13), 307(31), 325(47), 453(12) | 93(4), 137(100), 151(5), 245(9) | 93(100) | 14.97 | 12.28 |
|
| Methylgalloyl-galloyl hexoside | 7.38 |
| 497.09368 | 497.08902 | 4.66 | 183(6), 313(3), 345(100), 346(11), 465(11), 466(3) | 183(100) | 124(81), 168(100), 183(3) | 16.34 | 19.42 |
|
| Methylgalloyl-caffeoyl hexoside | 8.59 |
| 507.11441 | 507.10987 | 4.54 | 179(5), 183(6), 323(18), 345(100), 346(13), 916(13), 917(6) | 183(100) | 124(90), 168(100) | 5.63 | 2.33 |
|
| Methylgalloyl-coumaroyl hexoside | 9.21 |
| 491.11950 | 491.11539 | 4.11 | 183(14), 329(51), 330(10), 345(100), 346(13), 409(7), 457(9) | 183(100) | 124(71), 168(100), 183(3) | 5.09 | 2.37 |
|
| Trimethylellagic acid isomer 1 | 9.62 |
| 343.04594 | 343.04253 | 3.41 | 171(3), 297(4), 299(4), 315(3), 325(5), 328(100), 329(15) | 313(100), 314(9) | 285(41), 286(3), 298(100), 299(4) | 78.57 | 61.98 |
|
| Ellagic acid | 9.65 |
| 300.99899 | 300.99735 | 1.64 | 185(41), 229(83), 255(48), 257(100), 271(61), 284(38), 301(37) | 185(100), 186(12), 201(10), 213(18), 228(5), 229(70) | 141(100), 157(46) | 11.77 | ND |
|
| Trimethylellagic acid isomer 2 | 10.74 |
| 343.04594 | 343.04226 | 3.68 | 295(4), 297(3), 325(3), 328(100), 329(17), 330(3) | 313(100), 314(10) | 285(40), 298(100), 299(8) | 34.25 | 16.44 |
|
| mg/kg RE * | ||||||||||
|
| Quercetin 3- | 7.50 |
| 625.14102 | 625.13645 | 4.57 | 271(18), 300(15), 300(100), 301(50), 445(26), 463(10), 505(11) | 151(21), 179(25), 254(10), 255(53), 271(100), 272(21) | 199(32), 215(28), 227(79), 243(100), 271(14) | 2.57 | 112.39 |
|
| Kaempferol 3- | 7.81 |
| 609.14611 | 609.14166 | 4.45 | 255(11), 257(9), 284(47), 285(100), 286(11), 429(46), 430(8) | 151(47), 213(31), 229(42), 241(50), 256(47), 257(100) | 163(48), 187(13), 213(18), 229(100), 239(25) | 2.77 | 11.46 |
|
| Quercetin 3- | 7.99 |
| 609.14611 | 609.14278 | 3.33 | 255(5), 271(7), 299(5), 300(42), 301(100), 302(13), 343(8) | 151(78), 179(100), 256(10), 257(13), 272(13), 273(17) | 151(100) | 13.95 | 33.20 |
|
| Quercetin 3- | 8.31 |
| 463.08820 | 463.08349 | 4.71 | 300(12), 301(100), 302(11), 381(3), 445(4) | 151(77), 179(100), 255(46), 257(12), 271(72), 272(23) | 151(100) | 18.32 | 13.40 |
|
| Quercetin 3- | 8.31 |
| 477.06692 | 477.06196 | 4.96 | 301(100), 302(13), 315(7), 429(6), 431(3), 453(9) | 107(5), 151(80), 179(100), 193(5), 257(13), 273(20) | 151(100) | 5.05 | 6.75 |
|
| Kaempferol 7- | 8.41 |
| 593.15119 | 593.14656 | 4.63 | 257(3), 284(6), 285(100), 286(12) | 197(20), 213(25), 229(49), 241(33), 257(100), 267(47) | 163(75), 187(17), 213(32), 229(100), 239(29) | 35.26 | 28.72 |
|
| Isorhamnetin 3- | 8.48 |
| 623.16176 | 623.15692 | 4.84 | 255(3), 271(5), 300(14), 315(100), 316(13), 317(3) | 272(6), 287(5), 300(100) | 255(65), 271(100), 272(39) | 97.90 | 107.05 |
|
| Isorhamnetin 3- | 8.82 |
| 477.10385 | 477.09994 | 3.91 | 271(8), 285(9), 314(100), 315(45), 316(6), 357(17), 453(7) | 243(24), 271(74), 285(100), 286(50), 299(25), 300(44) | 270(100) | 11.10 | 6.40 |
* Compounds 1–19 were quantified as mg of gallic acid equivalents (GAE) per kg of fraction. Compounds 20–27 were quantified as mg of rutin equivalents (RE) per kg of fraction.